CBAN
Colony Bankcorp, Inc.
CBAN has slightly lower modeled downside risk, despite its lower overall score.
GS
The Goldman Sachs Group, Inc.
GS has a slight edge over CBAN overall on the model score.
CBAN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CBAN's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CBAN.
GS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| N/A | |
| N/A |
GS's revenue and profitability are currently strong. Free cash flow and net leverage aren't meaningful measures for financial services companies like GS.
CBAN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.9x | $20.30 | — |
| Cheap | 9.4x | $17.14 | -16% |
| Fair | 11x | $20.26 | -0.2% |
| Current | 11x | $20.30 | — |
| Expensive | 13x | $22.83 | +12% |
Historical ranges are pointers, not guarantees.
CBAN has the edge over GS in the historical PE scenario, which offers more potential upside but is not a forecast.
GS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.6x | $528 | -42% |
| Current | 13x | $914 | — |
| Forward | 13x | $914 | — |
| Fair | 14x | $940 | +2.9% |
| Expensive | 17x | $1,214 | +33% |
Historical ranges are pointers, not guarantees.
GS's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CBAN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CBAN, but weaker profitability.
GS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for GS, with profitability improving. However, they disagree widely on these estimates.
CBAN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.28 | +25% |
| Q3 2026 | $1.82 | +14% |
| Q2 2026 | $1.65 | +3.8% |
| Q1 2026 | $1.60 | +11% |
| Q4 2025 | $1.59 | +17% |
| Q3 2025 | $1.60 | +28% |
| Q2 2025 | $1.59 | +26% |
| Q1 2025 | $1.44 | +15% |
| Q4 2024 | $1.36 | +9.7% |
CBAN's earnings per share have climbed steadily: $1.82 over the past year, up 14% from the year before, and higher year over year for 13 quarters in a row.
GS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $72.35 | +4% |
| Q3 2026 | $69.58 | +41% |
| Q2 2026 | $64.82 | +43% |
| Q1 2026 | $54.75 | +27% |
| Q4 2025 | $51.32 | +27% |
| Q3 2025 | $49.22 | +44% |
| Q2 2025 | $45.37 | +45% |
| Q1 2025 | $43.08 | +68% |
| Q4 2024 | $40.54 | +77% |
GS has the edge over CBAN on earnings, with stronger typical year-over-year growth.
CBAN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.6M | +30% |
| Q2 2026 | $42M | +29% |
| Q1 2026 | $39.9M | +33% |
| Q4 2025 | $36.9M | +20% |
| Q3 2025 | $32.8M | +15% |
| Q2 2025 | $32.5M | +16% |
| Q1 2025 | $30M | +6.6% |
| Q4 2024 | $30.8M | +9.2% |
CBAN has the edge over GS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +9.1 points |
| Q2 2026 | 33% | +1.7 points |
| Q1 2026 | 26% | -1.3 points |
| Q4 2025 | 26% | -2.9 points |
| Q3 2025 | 22% | -2.4 points |
| Q2 2025 | 31% | +6.1 points |
| Q1 2025 | 28% | +3.6 points |
| Q4 2024 | 29% | +3.6 points |
CBAN's operating margin was 31% last quarter, up 9.1 points from the same quarter a year ago, near the top of its range since 2019.
GS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7B | +23% |
| Q2 2026 | $20.3B | +39% |
| Q1 2026 | $17.2B | +14% |
| Q4 2025 | $13.5B | -3% |
| Q3 2025 | $15.2B | +20% |
| Q2 2025 | $14.6B | +15% |
| Q1 2025 | $15.1B | +6% |
| Q4 2024 | $13.9B | +23% |
GS's revenue is growing: $18.7B last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | +2 points |
| Q2 2026 | 42% | +8.1 points |
| Q1 2026 | 38% | +0.2 points |
| Q4 2025 | 44% | +5.6 points |
| Q3 2025 | 36% | +4.1 points |
| Q2 2025 | 34% | +3.2 points |
| Q1 2025 | 37% | +0.6 points |
| Q4 2024 | 38% | +18 points |
GS has the edge over CBAN on profitability, with a higher operating margin.
CBAN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.7M | -67% |
| Q2 2026 | $8.2M | -48% |
| Q1 2026 | $53.8M | +206% |
| Q4 2025 | -$54.3M | -$50.5M |
| Q3 2025 | $14.1M | -30% |
| Q2 2025 | $15.8M | +1492% |
| Q1 2025 | $17.6M | +257% |
| Q4 2024 | -$3.8M | -174% |
CBAN has the edge over GS on cash generation, producing positive trailing cash flow while its opponent burns cash.
GS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +72% |
| Q2 2026 | $5.6B | +7.8% |
| Q1 2026 | -$32.4B | +$5.3B |
| Q4 2025 | -$16.8B | -136% |
| Q3 2025 | $2.1B | +$40.6B |
| Q2 2025 | $5.2B | -6.8% |
| Q1 2025 | -$37.7B | -$9.2B |
| Q4 2024 | $46.2B | +$75.1B |
GS's free cash flow was −$40B over the past year, against $15.8B the year before. Free cash flow isn't a meaningful measure for financial services companies like GS.
CBAN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +60.6K shares |
| 1 year | +22% | +3.8M shares |
| 3 years | +21% | +3.7M shares |
| 5 years | +123% | +11.7M shares |
| Available history | +132% | +12.1M shares |
CBAN has 21M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $1.8M |
| Q4 2025 | $779,000 |
| Q3 2025 | — |
| Q2 2025 | $959,000 |
| Q1 2025 | $630,000 |
| Q4 2024 | $540,000 |
CBAN spent $3M buying back its own shares over the past year, up 20% from the year before.
GS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -3.8M shares |
| 1 year | -4.4% | -13.9M shares |
| 3 years | -12% | -42.8M shares |
| 5 years | -15% | -52.8M shares |
| Available history | -20% | -74.4M shares |
GS has the edge over CBAN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3B |
| Q2 2026 | $4B |
| Q1 2026 | $5B |
| Q4 2025 | $3B |
| Q3 2025 | $2B |
| Q2 2025 | $3B |
| Q1 2025 | $4.4B |
| Q4 2024 | $2B |
GS spent $15B buying back its own shares over the past year, up 32% from the year before.
CBAN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.5x | High |
| Q2 2026 | 7.4x | High |
| Q1 2026 | 9.2x | High |
| Q4 2025 | 5.4x | High |
| Q3 2025 | 9.7x | High |
| Q2 2025 | 9.7x | High |
| Q1 2025 | 11.1x | High |
| Q4 2024 | 5.9x | High |
CBAN's net debt is about 8.5 years of its operating earnings (EBITDA), down from 9.7 years a year ago. Net leverage isn't a meaningful measure for financial services companies like CBAN.
GS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -5.4x | Net Cash |
| Q2 2026 | -6.1x | Net Cash |
| Q1 2026 | -6.7x | Net Cash |
| Q4 2025 | -6.4x | Net Cash |
| Q3 2025 | -3.5x | Net Cash |
| Q2 2025 | -3.1x | Net Cash |
| Q1 2025 | -3.9x | Net Cash |
| Q4 2024 | -4.7x | Net Cash |
GS has the edge over CBAN on leverage, with a lower net debt burden relative to earnings.
CBAN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.0 | Neutral |
| Stochastic | 25.3 | Neutral |
CBAN's weekly RSI is 48 (neutral) and its Stochastic is 25 (neutral).
GS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.5 | Neutral |
| Stochastic | 16.3 | Oversold |
GS's weekly RSI is 45 (neutral) and its Stochastic is 16 (oversold).
CBAN PE vs Financial Services Sector
| Metric | CBAN | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 14% below |
| PE % | 50 | 63 | 13 pts below |
CBAN has the edge over GS on valuation relative to its sector.
GS PE vs Financial Services Sector
| Metric | GS | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 0.8% above |
| PE % | 46 | 63 | 17 pts below |
GS is trading at 13x earnings, in line with the Financial Services sector's median of 13x, though its earnings don't support one.
CBAN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.3 | 0.2% above |
| 20 week MA | $20.9 | 2.9% below |
| 50 week MA | $20.1 | 0.9% above |
| 100 week MA | $18.2 | 12% above |
| 200 week MA | $15.1 | 34% above |
CBAN has the edge over GS on trend strength, trading above more of its moving averages.
GS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $895.5 | 2% above |
| 20 week MA | $977.4 | 6.5% below |
| 50 week MA | $945.4 | 3.4% below |
| 100 week MA | $804.5 | 14% above |
| 200 week MA | $602.7 | 52% above |
GS's trend is mixed: it's above three of its five weekly moving averages, and 52% above its 200-week average.
CBAN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.5 | $14.1 | -14% |
| 2021 | $14.1 | $16.8 | +19% |
| 2022 | $16.8 | $12.9 | -23% |
| 2023 | $12.9 | $13.3 | +3.1% |
| 2024 | $13.3 | $16.3 | +22% |
| 2025 | $16.3 | $18.1 | +11% |
| 2026 YTD | $18.1 | $20.3 | +12% |
CBAN has the edge over GS on returns for 2026, with the stronger performance.
GS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $230.7 | $256.2 | +11% |
| 2021 | $256.2 | $385.0 | +50% |
| 2022 | $385.0 | $345.5 | -10% |
| 2023 | $345.5 | $385.8 | +12% |
| 2024 | $385.8 | $576.2 | +49% |
| 2025 | $576.2 | $907.0 | +57% |
| 2026 YTD | $907.0 | $913.6 | +0.7% |
GS has finished higher in five of the last six years, two of them by more than 50%. It's up 0.7% so far in 2026.